TLDR:
- AtaCor Medical, a medical device company, raised $28M in Series C funding.
- The funding will support FDA submission and completion of a pilot study for their cardiac rhythm management system.
AtaCor Medical, based in San Clemente, CA, recently closed a $28M Series C financing round led by Arboretum Ventures and existing investors Longview Ventures, Hatteras Venture Partners, Catalyst Health Ventures, and BayMed Venture Partners. The company, led by CEO Rick Sanghera, is focused on advancing cardiac pacing and defibrillation lead technology with its proprietary extravascular cardiac rhythm management system.
The funds from this round will be used to support FDA submission for AtaCor’s extravascular temporary pacing lead system and the completion of a pilot study for the third generation EV-ICD lead system. This technology aims to provide the benefits of traditional implantable cardiac defibrillation and temporary pacing without placing leads or devices in the heart or vascular system, preserving the integrity of the heart for future cardiac care needs.
CEO Rick Sanghera expressed enthusiasm about the investment, stating that it will support the company’s efforts to bring their novel products to patients as they plan for upcoming clinical and regulatory milestones.
